bioLytical Laboratories, Inc.

Richmond,  BC 
  • Booth: 3290

Booth Profile

Our INSTI™ HIV test is supported by worldwide regulatory approvals including US FDA approval, Health Canada approval and CE mark in Europe. INSTI provides a highly accurate HIV test result in as little as 60 seconds. We have an active R&D program and our pipeline includes INSTI™ tests for diseases such as Hepatitis C and Syphilis. We also provide contract services to adapt the INSTI™ platform to meet custom functional and technical diagnostic testing requirements.

 Press Releases

  • bioLytical Showcases the World’s Fastest HIV Test at AACC Clinical Lab Expo

    bioLytical will be exhibiting its market leading line of INSTI rapid diagnostic tests for the first time at this year’s American Association for Clinical Chemistry (AACC) Annual Scientific Meeting & Clinical Lab Expo.  INSTI’s HIV and Syphilis point-of-care and self-tests are the world’s fastest tests, providing results in just 1-minute.

    Taking place from August 4-8, 2019 at the Anaheim Convention Center in Anaheim, California, AACC is the world’s largest event for laboratory medicine, showcasing cutting edge technologies and featuring some of the foremost leaders in the field.

    Launching its presence at AACC, bioLytical will be demonstrating its revolutionary INSTI product line which has enhanced workflows across clinical and non-clinical settings around the world. Backed by extensive scientific studies, the one-minute INSTI platform has earned worldwide recognition and regulatory approvals including US FDA Approval, Health Canada Approval, CE Mark and WHO Prequalification.

    The bioLytical booth #3290 will feature the full range of INSTI diagnostic tests, and the opportunity for attendees to meet the team behind some of the company’s most significant innovations. Highlighted at the booth will be:

    • INSTI HIV Test - rapid in vitro qualitative test for the detection of antibodies to HIV-1 and HIV-2 in whole blood, fingerstick blood, serum or plasma
    • INSTI Multiplex HIV/Syphilis Test - rapid in vitro qualitative test for the simultaneous detection of antibodies to Treponema pallidum, HIV-1 and HIV-2 in whole blood, fingerstick blood, serum or plasma
    • INSTI HIV Self Test - a consumer facing home test for the detection of antibodies to HIV-1 and HIV-2 using a single drop of blood

    Through the INSTI HIV Self Test bioLytical offers the opportunity to discover a diagnostic product that is growing in significance as Health Bodies around the world embrace new and innovative technologies to reach global targets to end the AIDS epidemic. The INSTI Multiplex Test is also becoming an increasingly vital tool as rates of Syphilis and HIV/Syphilis coinfection rise in many regions, including the United States.

    bioLytical’s powerful INSTI platform is built on disruptive immunofiltration “flow-through” technology, unlike typical diagnostic tests which use lateral flow.  When performing the test, reagents are added to the unique membrane unit and flow through into an absorbent pad for instant results.  The entire procedure from sampling to result can be completed in as little as 1 minute and the test can be performed in a wide variety of settings.  Not only does INSTI provide flexibility and convenience for the clinician and the patient, it also helps to break down the barriers that have traditionally prevented some populations from accessing testing and allows more time for pre-and post-test counseling, prevention education and linkage to care.

    bioLytical has experienced unprecedented growth in recent years and in the past 12 months has past achieved milestones including earning WHO Prequalification for the INSTI HIV Self Test and MDSAP Certification, the highest quality standard in the medical device industry.